Illinois 2025-2026 Regular Session

Illinois House Bill HB3001 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027. LRB104 08415 BAB 18466 b A BILL FOR 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u 215 ILCS 5/356u Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027. LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b A BILL FOR
2	2	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED:
3	3	215 ILCS 5/356u 215 ILCS 5/356u
4	4	215 ILCS 5/356u
5	5	Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
6	6	LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b
7	7	LRB104 08415 BAB 18466 b
8	8	A BILL FOR
9	9	HB3001LRB104 08415 BAB 18466 b HB3001 LRB104 08415 BAB 18466 b
10	10	HB3001 LRB104 08415 BAB 18466 b
11	11	1 AN ACT concerning regulation.
12	12	2 Be it enacted by the People of the State of Illinois,
13	13	3 represented in the General Assembly:
14	14	4 Section 5. The Illinois Insurance Code is amended by
15	15	5 changing Section 356u as follows:
16	16	6 (215 ILCS 5/356u)
17	17	7 Sec. 356u. Pap tests and prostate cancer screenings.
18	18	8 (a) A group policy of accident and health insurance that
19	19	9 provides coverage for hospital or medical treatment or
20	20	10 services for illness on an expense-incurred basis and is
21	21	11 amended, delivered, issued, or renewed after January 1, 2024
22	22	12 shall provide coverage, without imposing a deductible,
23	23	13 coinsurance, copayment, or any other cost-sharing requirement,
24	24	14 for all of the following:
25	25	15 (1) An annual cervical smear or Pap smear test for all
26	26	16 insureds.
27	27	17 (2) An annual prostate cancer screening for insureds
28	28	18 upon the recommendation of a physician licensed to
29	29	19 practice medicine in all its branches for:
30	30	20 (A) asymptomatic individuals age 50 and over;
31	31	21 (B) African-American individuals age 40 and over;
32	32	22 and
33	33	23 (C) individuals age 40 and over with a family
34	34
35	35
36	36
37	37	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED:
38	38	215 ILCS 5/356u 215 ILCS 5/356u
39	39	215 ILCS 5/356u
40	40	Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
41	41	LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b
42	42	LRB104 08415 BAB 18466 b
43	43	A BILL FOR
44	44
45	45
46	46
47	47
48	48
49	49	215 ILCS 5/356u
50	50
51	51
52	52
53	53	LRB104 08415 BAB 18466 b
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63	HB3001 LRB104 08415 BAB 18466 b
64	64
65	65
66	66	HB3001- 2 -LRB104 08415 BAB 18466 b HB3001 - 2 - LRB104 08415 BAB 18466 b
67	67	HB3001 - 2 - LRB104 08415 BAB 18466 b
68	68	1 history of or genetic predisposition to prostate
69	69	2 cancer.
70	70	3 (3) Surveillance tests for ovarian cancer for insureds
71	71	4 who are at risk for ovarian cancer.
72	72	5 (b) This Section shall not apply to agreements, contracts,
73	73	6 or policies that provide coverage for a specified disease or
74	74	7 other limited benefit coverage.
75	75	8 (c) This Section does not apply to coverage of prostate
76	76	9 cancer screenings to the extent such coverage would disqualify
77	77	10 a high-deductible health plan from eligibility for a health
78	78	11 savings account pursuant to Section 223 of the Internal
79	79	12 Revenue Code.
80	80	13 (d) For the purposes of this Section:
81	81	14 "At risk for ovarian cancer" means:
82	82	15 (1) having a family history (i) with one or more
83	83	16 first-degree relatives with ovarian cancer, (ii) of
84	84	17 clusters of relatives with breast cancer, or (iii) of
85	85	18 nonpolyposis colorectal cancer; or
86	86	19 (2) testing positive for BRCA1 or BRCA2 mutations; or .
87	87	20 (3) having a high level of CA-125, as indicated by a
88	88	21 blood test screening.
89	89	22 "Prostate cancer screening" means medically viable methods
90	90	23 for the detection and diagnosis of prostate cancer, including
91	91	24 a digital rectal exam and the prostate-specific antigen test
92	92	25 and associated laboratory work. "Prostate cancer screening"
93	93	26 includes medically necessary subsequent follow-up testing as
94	94
95	95
96	96
97	97
98	98
99	99	HB3001 - 2 - LRB104 08415 BAB 18466 b
100	100
101	101
102	102	HB3001- 3 -LRB104 08415 BAB 18466 b HB3001 - 3 - LRB104 08415 BAB 18466 b
103	103	HB3001 - 3 - LRB104 08415 BAB 18466 b
104	104	1 directed by a health care provider, including, but not limited
105	105	2 to:
106	106	3 (1) urinary analysis;
107	107	4 (2) serum biomarkers; and
108	108	5 (3) medical imaging, including, but not limited to,
109	109	6 magnetic resonance imaging.
110	110	7 "Surveillance tests for ovarian cancer" means all
111	111	8 medically viable methods for the detection and diagnosis of
112	112	9 ovarian cancer, including, but not limited to, ultrasounds,
113	113	10 magnetic resonance imagings (MRIs), x-rays, computed
114	114	11 tomography (CT) scans, and CA-125 blood test screenings.
115	115	12 annual screening using (i) CA-125 serum tumor marker testing,
116	116	13 (ii) transvaginal ultrasound, (iii) pelvic examination.
117	117	14 (Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25.)
118	118
119	119
120	120
121	121
122	122
123	123	HB3001 - 3 - LRB104 08415 BAB 18466 b